Epkinly
Asset
Bispecific CD20-directed CD3 T-cell engager antibody
- Stage
- Phase 3
- Modality
- Antibody
- Target
- Apoptosis
- 3
- Indications
- 0
- Trials
- 2
- Developers
Indications
3Diffuse large B-cell lymphoma
Phase 3, endpoints.news, 6 Oct 2026
DLBCL
Phase 3, biopharmadive.com, 6 Oct 2026
First-line diffuse large b-cell lymphoma
Phase 3, endpoints.news, 6 Oct 2026
In the full profile
- Targets and what it contains4
- Owner and partners4
- Evidence for its targets2
- Competitors6
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026, 2 sources